ALIMTA 100 mg powder for concentrate for solution for infusion clinical trials

An open-label, dose-escalation, phase I/II study to assess the safety, the tolerability, the immunogenicity and the preliminary clinical activity of the therapeutic cancer vaccine, PDC*lung01, associated or not with anti-PD-1 treatment in patients with non-small-cell lung cancer (NSCLC)

This study is testing a new cancer 'vaccine' called PDC*lung01 for non-small-cell lung cancer. It checks if it's safe, how well people can tolerate it, and if it helps fight the cancer, sometimes with another drug called anti-PD-1.